Chronic, but Not Acute, Dosing of Antipsychotic Drugs Alters Neurotensin Binding in Rat Brain Regions

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2000 Oct 29

PMID 11053221

Authors

P E Holtom

P L Needham

G W Bennett

S Aspley

Affiliations

Soon will be listed here.

Abstract

The present study compared high affinity neurotensin (NT) binding in rat brain following acute or chronic treatment with the classical antipsychotic, haloperidol, and the newer antipsychotic drugs, clozapine and zotepine. Drugs were given orally, as an acute treatment (1 dose) or chronically (21 day dosing) and binding to the NT high affinity receptor was examined in three brain regions; striatum, nucleus accumbens/olfactory tubercle and frontal cortex. Acute dosing with either vehicle, haloperidol, clozapine or zotepine produced no significant changes in NT binding from controls (naïve rats). Chronic (21 day) dosing resulted in an increase in the K:(D:) and B(max) of high affinity receptors in the striatum following haloperidol, but not clozapine, zotepine or vehicles. In contrast, the newer antipsychotics, clozapine and zotepine but not haloperidol or vehicles, significantly altered NT binding in the nucleus accumbens/olfactory tubercle by decreasing the K:(D:) and B(max). Further differentiation between the two newer antipsychotic drugs occurred in the frontal cortex. Clozapine had no significant effect on NT binding, whereas zotepine significantly reduced the K:(D:) of the high affinity receptor with no alteration in B(max). The antipsychotic drugs tested did not interact directly with the NT high affinity receptor. Therefore, they must be acting indirectly via an alternative receptor mechanism to alter NT high affinity binding. In accordance with previously reported NT/dopamine receptor interactions, this would suggest cross-talk between these systems. Overall, these data demonstrate that chronic, but not acute, administration of antipsychotic drugs alters NT binding in the rat brain. In addition, anatomical differences in NT binding arise according to the antipsychotic drug under test. This may be predictive of drug side-effect profile, antipsychotic efficacy or atypicality.

References

Brun P, Steinberg R, Le Fur G, Soubrie P . Blockade of neurotensin receptor by SR 48692 potentiates the facilitatory effect of haloperidol on the evoked in vivo dopamine release in the rat nucleus accumbens. J Neurochem. 1995; 64(5):2073-9. DOI: 10.1046/j.1471-4159.1995.64052073.x. View

Lindstrom L, Widerlov E, Bisette G, Nemeroff C . Reduced CSF neurotensin concentration in drug-free schizophrenic patients. Schizophr Res. 1988; 1(1):55-9. DOI: 10.1016/0920-9964(88)90040-0. View

Herve D, Tassin J, Studler J, Dana C, Kitabgi P, Vincent J . Dopaminergic control of 125I-labeled neurotensin binding site density in corticolimbic structures of the rat brain. Proc Natl Acad Sci U S A. 1986; 83(16):6203-7. PMC: 386468. DOI: 10.1073/pnas.83.16.6203. View

Blaha C, Coury A, Fibiger H, Phillips A . Effects of neurotensin on dopamine release and metabolism in the rat striatum and nucleus accumbens: cross-validation using in vivo voltammetry and microdialysis. Neuroscience. 1990; 34(3):699-705. DOI: 10.1016/0306-4522(90)90176-5. View

Kane J, HONIGFELD G, Singer J, Meltzer H . Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45(9):789-96. DOI: 10.1001/archpsyc.1988.01800330013001. View

Breslin N, Suddath R, Bissette G, Nemeroff C, Lowrimore P, Weinberger D . CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. Schizophr Res. 1994; 12(1):35-41. DOI: 10.1016/0920-9964(94)90082-5. View

Tanganelli S, Li X, Ferraro L, von Euler G, OConnor W, Bianchi C . Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum. Eur J Pharmacol. 1993; 230(2):159-66. DOI: 10.1016/0014-2999(93)90798-m. View

Goedert M, Iversen S, Emson P . The effects of chronic neuroleptic treatment on neurotensin-like immunoreactivity in the rat central nervous system. Brain Res. 1985; 335(2):334-6. DOI: 10.1016/0006-8993(85)90488-3. View

Merchant K . c-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum. Mol Cell Neurosci. 1994; 5(4):336-44. DOI: 10.1006/mcne.1994.1040. View

10.

Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H . Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol. 1996; 6 Suppl 2:S13-20. DOI: 10.1016/0924-977x(96)00010-7. View

11.

Li X, von Euler G, Hedlund P, Finnman U, Fuxe K . The C-terminal neurotensin-(8-13) fragment potently modulates rat neostriatal dopamine D2 receptors. Eur J Pharmacol. 1993; 234(1):125-8. DOI: 10.1016/0014-2999(93)90716-u. View

12.

Uhl G, Kuhar M . Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra. Nature. 1984; 309(5966):350-2. DOI: 10.1038/309350a0. View

13.

Trovero F, Herve D, Blanc G, Glowinski J, Tassin J . Different regulations of dopaminergic (D1) receptors and neurotensinergic binding sites in the rat prefrontal cortex. Neurosci Lett. 1991; 127(2):198-202. DOI: 10.1016/0304-3940(91)90793-s. View

14.

Chapman M, See R, Bissette G . Neurotensin increases extracellular striatal dopamine levels in vivo. Neuropeptides. 1992; 22(3):175-83. DOI: 10.1016/0143-4179(92)90160-x. View

15.

LJUNGBERG T, Ungerstedt U . A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. Pharmacol Biochem Behav. 1985; 23(3):479-85. DOI: 10.1016/0091-3057(85)90025-5. View

16.

Iversen L, Lee C, Gilbert R, Hunt S, Emson P . Regulation of neuropeptide release. Proc R Soc Lond B Biol Sci. 1980; 210(1178):91-111. DOI: 10.1098/rspb.1980.0121. View

17.

Fuxe K, von Euler G, Agnati L, Merlo Pich E, OConnor W, Tanganelli S . Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. Ann N Y Acad Sci. 1992; 668:186-204. DOI: 10.1111/j.1749-6632.1992.tb27350.x. View

18.

Adler L, Angrist B, Reiter S, Rotrosen J . Neuroleptic-induced akathisia: a review. Psychopharmacology (Berl). 1989; 97(1):1-11. DOI: 10.1007/BF00443404. View

19.

Carraway R, Leeman S . The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem. 1973; 248(19):6854-61. View

20.

Fuxe K, Agnati L, Martire M, Neumeyer A, Benfenati F, Frey P . Studies of neurotensin-dopamine receptor interactions in striatal membranes of the male rat. The influence of 6-hydroxydopamine-induced dopamine receptor supersensitivity. Acta Physiol Scand. 1986; 126(1):147-9. DOI: 10.1111/j.1748-1716.1986.tb07798.x. View